Literature DB >> 21373987

Predictive and prognostic markers in colorectal cancer.

Ben George1, Scott Kopetz.   

Abstract

Colorectal cancer (CRC) has a complex pathogenesis involving multiple sequential steps with accumulation of genetic alterations including mutations, gene amplification, and epigenetic changes. Treatment of CRC has undergone a paradigm shift over the past decade due in part to a better understanding of the biology of the disease and development of newer drugs including biologic agents. In the era of personalized medicine, it is attractive to investigate the molecular pathways leading to colorectal cancer tumorigenesis, thus raising the possibility of identifying novel therapeutic targets. It has intuitive appeal to hypothesize that biomarkers that have prognostic and/or predictive value are those that are intimately connected to the pathogenesis of CRC. In this article, we focus on prognostic and predictive markers in CRC that have a substantial body of data in support of their potential role in routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21373987     DOI: 10.1007/s11912-011-0162-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  90 in total

1.  The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

Authors:  A Fariña-Sarasqueta; G van Lijnschoten; E Moerland; G-J Creemers; V E P P Lemmens; H J T Rutten; A J C van den Brule
Journal:  Ann Oncol       Date:  2010-05-25       Impact factor: 32.976

2.  5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems.

Authors:  Franziska Fischer; Katja Baerenfaller; Josef Jiricny
Journal:  Gastroenterology       Date:  2007-09-14       Impact factor: 22.682

3.  K-ras mutations and cetuximab in colorectal cancer.

Authors:  Maher Albitar; Chenhsiung Yeh; Wanlong Ma
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

4.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

Review 5.  The epidermal growth factor receptor pathway: a model for targeted therapy.

Authors:  Maurizio Scaltriti; José Baselga
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

6.  Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas.

Authors:  P Zauber; M Sabbath-Solitare; S P Marotta; D T Bishop
Journal:  Mol Pathol       Date:  2003-06

7.  Identification of a chromosome 18q gene that is altered in colorectal cancers.

Authors:  E R Fearon; K R Cho; J M Nigro; S E Kern; J W Simons; J M Ruppert; S R Hamilton; A C Preisinger; G Thomas; K W Kinzler
Journal:  Science       Date:  1990-01-05       Impact factor: 47.728

8.  EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.

Authors:  F Cappuzzo; G Finocchiaro; E Rossi; P A Jänne; C Carnaghi; C Calandri; K Bencardino; C Ligorio; F Ciardiello; T Pressiani; A Destro; M Roncalli; L Crino; W A Franklin; A Santoro; M Varella-Garcia
Journal:  Ann Oncol       Date:  2007-10-31       Impact factor: 32.976

9.  Allelic loss of chromosome 18q and prognosis in colorectal cancer.

Authors:  J Jen; H Kim; S Piantadosi; Z F Liu; R C Levitt; P Sistonen; K W Kinzler; B Vogelstein; S R Hamilton
Journal:  N Engl J Med       Date:  1994-07-28       Impact factor: 91.245

10.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Authors:  F Loupakis; A Ruzzo; C Cremolini; B Vincenzi; L Salvatore; D Santini; G Masi; I Stasi; E Canestrari; E Rulli; I Floriani; K Bencardino; N Galluccio; V Catalano; G Tonini; M Magnani; G Fontanini; F Basolo; A Falcone; F Graziano
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more
  21 in total

1.  Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.

Authors:  Kang Sun; Aixia Gong; Pin Liang
Journal:  Tumour Biol       Date:  2014-10-30

2.  Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.

Authors:  Georgios Antonios Margonis; Yuhree Kim; Gaya Spolverato; Aslam Ejaz; Rohan Gupta; David Cosgrove; Robert Anders; Georgios Karagkounis; Michael A Choti; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2015-08       Impact factor: 14.766

3.  Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer.

Authors:  Angela N Bartley; Hui Yao; Bedia A Barkoh; Cristina Ivan; Bal M Mishra; Asif Rashid; George A Calin; Rajyalakshmi Luthra; Stanley R Hamilton
Journal:  Clin Cancer Res       Date:  2011-09-23       Impact factor: 12.531

4.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

5.  Analysis of colorectal cancer morphology in relation to sex, age, location, and family history.

Authors:  Sam Ghazi; Ulrik Lindforss; Greger Lindberg; Elisabeth Berg; Annika Lindblom; Nikos Papadogiannakis
Journal:  J Gastroenterol       Date:  2012-01-18       Impact factor: 7.527

Review 6.  Evolving notions on immune response in colorectal cancer and their implications for biomarker development.

Authors:  Fabio Grizzi; Gianluca Basso; Elena Monica Borroni; Tommaso Cavalleri; Paolo Bianchi; Sanja Stifter; Maurizio Chiriva-Internati; Alberto Malesci; Luigi Laghi
Journal:  Inflamm Res       Date:  2018-01-10       Impact factor: 4.575

7.  Primary tumor location as a prognostic factor in metastatic colorectal cancer.

Authors:  Fotios Loupakis; Dongyun Yang; Linda Yau; Shibao Feng; Chiara Cremolini; Wu Zhang; Martin K H Maus; Carlotta Antoniotti; Christiane Langer; Stefan J Scherer; Thomas Müller; Herbert I Hurwitz; Leonard Saltz; Alfredo Falcone; Heinz-Josef Lenz
Journal:  J Natl Cancer Inst       Date:  2015-02-24       Impact factor: 13.506

8.  Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.

Authors:  Ryota Nakanishi; Jun Harada; Munkhbold Tuul; Yan Zhao; Koji Ando; Hiroshi Saeki; Eiji Oki; Takefumi Ohga; Hiroyuki Kitao; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2012-11-29       Impact factor: 3.402

Review 9.  Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review.

Authors:  Rebeca Sanz-Pamplona; Antoni Berenguer; David Cordero; Samantha Riccadonna; Xavier Solé; Marta Crous-Bou; Elisabet Guinó; Xavier Sanjuan; Sebastiano Biondo; Antonio Soriano; Giuseppe Jurman; Gabriel Capella; Cesare Furlanello; Victor Moreno
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

Review 10.  Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse.

Authors:  Won Kyung Kang; Jin Kwon Lee; Seong Taek Oh; Sung Hak Lee; Chan Kwon Jung
Journal:  BMC Gastroenterol       Date:  2015-01-22       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.